| dbo:abstract |
كارلوماب هو جسم مضاد وحيد النسيلة مصمم لعلاج الأورام والأمراض المناعية. طورته شركة جونسون وجونسون. (ar) Carlumab (alternate identifier CNTO 888) is a discontinued human recombinant monoclonal antibody (type IgG1 kappa) that targets human CC chemokine ligand 2 (CCL2)/monocyte chemoattractant protein (MCP1). Carlumab was under development for use in the treatment of oncology and immune indications and was studied for application in systemic sclerosis, atherosclerosis, diabetic nephropathy, liver fibrosis and type 2 diabetes. The inhibitory binding of Carlumab to CCL2 was hypothesized to inhibit angiogenesis and consequently modulate tumor cell proliferation. Studies focusing on the effects of Carlumab have been performed in vitro on cell lines and in vivo on mice and in humans including phase 1 and phase 2 clinical trials evaluating the efficacy, safety and dose requirements of the drug. Clinical trials for Carlumab include studies of idiopathic pulmonary fibrosis, castration-resistant metastatic prostate cancer and solid tumors. Carlumab was being developed by Janssen Biotech prior to discontinuation in 2012 due to limited success in clinical trials. (en) |
| dbo:casNumber |
915404-94-3 |
| dbo:fdaUniiCode |
6TC1BB2EV9 |
| dbo:kegg |
D09877 |
| dbo:wikiPageID |
33023919 (xsd:integer) |
| dbo:wikiPageLength |
7185 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1036461206 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Pulmonary_fibrosis dbr:MCP-1 dbr:Monoclonal_antibody dbr:Clinical_trial dbr:Prostate_cancer dbr:Angiogenesis dbr:Diabetic_nephropathy dbr:Atherosclerosis dbr:Systemic_scleroderma dbr:Diabetes dbr:CCL2 dbr:Liver_fibrosis |
| dbp:atcPrefix |
none (en) |
| dbp:c |
6442 (xsd:integer) |
| dbp:casNumber |
915404 (xsd:integer) |
| dbp:chemspiderid |
none (en) |
| dbp:h |
9966 (xsd:integer) |
| dbp:kegg |
D09877 (en) |
| dbp:mabType |
mab (en) |
| dbp:n |
1706 (xsd:integer) |
| dbp:o |
2018 (xsd:integer) |
| dbp:s |
40 (xsd:integer) |
| dbp:source |
u (en) |
| dbp:target |
dbr:MCP-1 |
| dbp:type |
mab (en) |
| dbp:unii |
6 (xsd:integer) |
| dbp:verifiedfields |
changed (en) |
| dbp:verifiedrevid |
460019588 (xsd:integer) |
| dbp:watchedfields |
changed (en) |
| dbp:wikiPageUsesTemplate |
dbt:Antineoplastic-drug-stub dbt:Clear dbt:Drugbox dbt:Reflist dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Keggcite dbt:Monoclonals_for_immune_system dbt:Chemokine_receptor_modulators dbt:Monoclonal-antibody-stub |
| gold:hypernym |
dbr:Antibody |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459 |
| rdfs:comment |
كارلوماب هو جسم مضاد وحيد النسيلة مصمم لعلاج الأورام والأمراض المناعية. طورته شركة جونسون وجونسون. (ar) Carlumab (alternate identifier CNTO 888) is a discontinued human recombinant monoclonal antibody (type IgG1 kappa) that targets human CC chemokine ligand 2 (CCL2)/monocyte chemoattractant protein (MCP1). Carlumab was under development for use in the treatment of oncology and immune indications and was studied for application in systemic sclerosis, atherosclerosis, diabetic nephropathy, liver fibrosis and type 2 diabetes. Carlumab was being developed by Janssen Biotech prior to discontinuation in 2012 due to limited success in clinical trials. (en) |
| rdfs:label |
كارلوماب (ar) Carlumab (en) |
| owl:sameAs |
freebase:Carlumab yago-res:Carlumab wikidata:Carlumab dbpedia-ar:Carlumab dbpedia-fa:Carlumab https://global.dbpedia.org/id/4gFcx |
| prov:wasDerivedFrom |
wikipedia-en:Carlumab?oldid=1036461206&ns=0 |
| foaf:isPrimaryTopicOf |
wikipedia-en:Carlumab |
| is dbo:wikiPageWikiLink of |
dbr:C6442H9966N1706O2018S40 dbr:List_of_therapeutic_monoclonal_antibodies dbr:List_of_drugs:_C–Ca |
| is foaf:primaryTopic of |
wikipedia-en:Carlumab |